Moderna’s RSV shot for adults 60 and older was approved by the Food and Drug Administration on Friday, joining a growing group of vaccines protecting against the major respiratory threat.
Why it matters: It’s Moderna’s second approved product, and company officials said it’s the first mRNA vaccine approved for a disease other than COVID-19.
Driving the news: Moderna expects to launch its vaccine, mResvia, in time for respiratory virus season this fall.